HEPATITIS B
Clinical trials for HEPATITIS B explained in plain language.
Never miss a new study
Get alerted when new HEPATITIS B trials appear
Sign up with your email to follow new studies for HEPATITIS B, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Hepatitis b drug trial halted early
Disease control TerminatedThis early-stage study tested an experimental drug called ARC-521 in healthy volunteers and people with chronic hepatitis B. The goal was to check safety and how the body processes the drug. The study was terminated early, so results are limited. It involved 47 participants and w…
Matched conditions: HEPATITIS B
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 05:02 UTC
-
Experimental hepatitis b drug shows promise in lowering virus markers
Disease control TerminatedThis study tested an experimental drug called ARC-520 in adults with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could further reduce hepatitis B surface antigen levels in the blood. The trial was stopped early…
Matched conditions: HEPATITIS B
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Hepatitis b drug trial halted: ARC-520 shows promise but study stopped early
Disease control TerminatedThis study tested an experimental drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if ARC-520 could lower hepatitis B surface antigen levels more than placebo. The trial was terminated early, so res…
Matched conditions: HEPATITIS B
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
Hepatitis b drug trial halted midway
Disease control TerminatedThis study tested an experimental drug called ARC-520 in people with chronic hepatitis B. Some participants received ARC-520 alone, while others got it with standard treatments like entecavir or tenofovir. The goal was to see if the drug could lower hepatitis B surface antigen le…
Matched conditions: HEPATITIS B
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Hepatitis b drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could safely lower a key virus marker (HBsAg) in the blood. Only 12 people who had shown some ini…
Matched conditions: HEPATITIS B
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Hepatitis b drug combo study halted early – what we know
Disease control TerminatedThis early-stage study tested a new drug (GSK3965193) for chronic hepatitis B, first in healthy volunteers and then in people with the infection. Some participants also received a second drug (bepirovirsen). The goal was to check safety and how well the drugs lower the virus. The…
Matched conditions: HEPATITIS B
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Real-World hepatitis b study aims to track patient outcomes
Knowledge-focused TerminatedThis study observed over 1,700 adults with chronic hepatitis B at regular clinics in the US and Canada. Researchers collected information on how the disease progresses, which treatments are used, and how well they work. The goal was to learn more about the real-world management a…
Matched conditions: HEPATITIS B
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 05:06 UTC
-
Vaccine study aims to unlock secrets of Long-Term immunity
Knowledge-focused TerminatedThis study looked at how the hepatitis B vaccine triggers the body's immune system, specifically focusing on memory B cells that help provide long-lasting protection. Healthy volunteers who had never been vaccinated against hepatitis B received the vaccine, and researchers analyz…
Matched conditions: HEPATITIS B
Phase: PHASE4 • Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated May 26, 2026 05:00 UTC